AI-generated from publicly available materials.Bioptimus, a Paris-based AI biotech firm, has partnered with Cancer Research Horizons to enhance AI-driven precision medicine through access to extensive colorectal cancer datasets.
The collaboration grants Bioptimus access to the S:CORT dataset, which encompasses over 1,750 patient profiles and integrates multiple data modalities, including imaging and genomic information. This resource is part of Bioptimus's broader initiative, STELA, aimed at constructing a comprehensive multimodal tissue atlas that links clinical data with biological insights. The S:CORT dataset's multifaceted approach captures both the biological intricacies and long-term therapeutic responses of patients, marking a significant step forward in precision medicine.
Founded in early 2024 by a team from Google DeepMind and Owkin, Bioptimus has rapidly secured substantial funding, totaling $76 million within its first year. This financial backing is critical as the company seeks to build a data infrastructure that surpasses existing spatial biology resources by a factor of twenty.
This partnership with Cancer Research Horizons represents Bioptimus's third collaboration since launching STELA. The CEO of Bioptimus, Jean-Philippe Vert, emphasized the importance of the S:CORT dataset in the ongoing development of their AI foundation model for biology, which aims to facilitate the translation of scientific discoveries into tangible clinical advancements. The initiative seeks to dismantle data silos, thereby accelerating the integration of research into practical healthcare solutions.